证券代码：301239 证券简称：普瑞眼科 公告编号：2025-037 普瑞眼科医院集团股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》和深圳证券交 易所印发的《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》的规定，现将普瑞眼科医院集团股份有限公司（以下简称"公司"或 "本公司"）募集资金 2025 年半年度存放与使用情况专项说明如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕587 号），本公司由主承销商 国泰海通证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通 股（A 股）股票 3,740.4762 万股，发行价为每股人民币 33.65 元，共计募集资 金 125,867.02 万元，坐扣承销费用 10,673.52 万元后的募集资金为 115,193.50 万 ...

普瑞眼科医院集团股份有限公司 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上 | 上市公司核 | 2025年期初 | 2025年度1-6月 | 2025年度1-6月 | 2025年度1-6月 | 2025年6月末 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 市公司的关 | 算的会计科 | 占用资金余 | 占用累计发生 | 占用资金的利 | 偿还累计发生 | 占用资金余 | 成原因 | | | | | 联关系 | 目 | 额 | 金额（不含利 | 息（如有） | 金额 | 额 | | | | | | | | | 息） | | | | | | | 控股股东、实际控制 | | | | - | - | - | - | | - | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | | - | | | 前控股股东、 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-034 普瑞眼科医院集团股份有限公司 第三届董事会第三十二次会议决议公告 一、董事会会议召开情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第三 十二次会议通知于2025年8月15日以书面、电子邮件的方式向全体董事发出并送 达，会议于2025年8月27日以现场结合通讯方式召开。本次会议应出席董事7人， 实际出席董事7人。会议由董事长徐旭阳先生主持，公司全体高级管理人员列席 会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律、法规、规范性文件以及《公司章程》的有关规定，所作决议合法有效。 二、董事会会议审议情况 经与会董事认真审议，表决了以下议案： （一）审议通过《关于公司<2025年半年度报告>全文及其摘要的议案》 经审议，董事会认为：公司《2025年半年度报告》全文及摘要符合法律、 行政法规、中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整 地反映了公司的经营情况，不存在虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《2025年半 年 ...

国泰海通证券股份有限公司 关于普瑞眼科医院集团股份有限公司 使用部分超募资金新建成都锦江普瑞眼科医院项目 的核查意见 国泰海通证券股份有限公司(以下简称"国泰海通"或"保荐机构")作为 普瑞眼科医院集团股份有限公司(以下简称"普瑞眼科"或"公司")首次公开 发行股票并在创业板上市持续督导保荐机构,根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号--创业板上市公司规范运作》《上市公司募集资金监管规则》 等有关规定对普瑞眼科关于使用部分超募资金新建成都锦江普瑞眼科医院项目 的事项进行了核查，具体核查意见如下: 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕587号）同意注册，公司首次 公开发行人民币普通股（A股）股票37,404,762股，每股面值人民币1.00元，每 股发行价格为33.65元，募集资金总额为1,258,670,241.30元，扣除发行费用（含 税）后，实际募集资金净额为1,098,935,692.69元。天健会计师事务所（特殊普 通合伙 ...

Core Viewpoint - The company reported a slight increase in revenue but a significant decline in net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue reached 1.459 billion yuan, representing a year-on-year growth of 2.74% [1] - The net profit attributable to shareholders was 14.6675 million yuan, showing a year-on-year decrease of 66.12% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 20.7809 million yuan, down 54.14% year-on-year [1] - The basic earnings per share stood at 0.0985 yuan [1]

Core Insights - The company reported a revenue of 1.459 billion yuan for the first half of 2025, representing a year-on-year growth of 2.74% [1] - The net profit attributable to shareholders decreased by 66.12% to 14.6675 million yuan [1] - The net profit attributable to shareholders after excluding non-recurring gains and losses fell by 54.14% to 20.7809 million yuan [1] - The basic earnings per share stood at 0.0985 yuan [1]

Group 1 - The company, Purui Eye Hospital, announced on August 28 that it is applying for bank credit guarantees for its wholly-owned subsidiary, with a total external guarantee amount of approximately 765 million RMB, which includes this application [1] - The total external guarantee balance is approximately 548 million RMB, accounting for 26.1% of the company's audited net assets for the year 2024 [1] - For the fiscal year 2024, the company's revenue composition shows that the medical industry accounts for 99.31% of its total revenue, while other businesses contribute 0.69% [1] Group 2 - As of the report date, the market capitalization of Purui Eye Hospital is 6.4 billion RMB [2]

Core Insights - The company reported a revenue of 1.459 billion yuan for the first half of 2025, representing a year-on-year growth of 2.74% [1] - The net profit for the same period was 14.6675 million yuan, showing a significant decline of 66.12% compared to the previous year [1] Financial Performance - Revenue: 1.459 billion yuan, up 2.74% year-on-year [1] - Net Profit: 14.6675 million yuan, down 66.12% year-on-year [1]

Core Viewpoint - The company has approved the use of part of the raised funds from its initial public offering to establish a new eye hospital in Chengdu, indicating a strategic expansion in the healthcare sector [1] Group 1: Project Details - The company will invest a total of RMB 22.82 million from the raised funds for the Chengdu Jinjiang Puri Eye Hospital project [1] - The total investment for the project is RMB 52.87 million, with the raised funds covering a significant portion [1] - The project will be implemented by Chengdu Jinjiang Puri Eye Hospital Co., Ltd., a wholly-owned subsidiary of the company [1] Group 2: Financial and Operational Aspects - The construction period for the project is estimated to be 11 months [1] - The company expects to recover the investment cost by the eighth year of operation [1]

Financial Performance - The company's operating revenue for the current reporting period is ¥1,459,262,003.44, representing a 2.74% increase compared to ¥1,420,361,520.54 in the same period last year[19]. - Net profit attributable to shareholders decreased by 66.12% to ¥14,667,471.77 from ¥43,294,484.53 year-on-year[19]. - The net cash flow from operating activities decreased by 11.60% to ¥245,191,811.13 compared to ¥277,369,046.33 in the previous year[19]. - Basic and diluted earnings per share fell by 66.03% to ¥0.0985 from ¥0.29 in the same period last year[19]. - The total assets at the end of the reporting period increased by 0.29% to ¥4,611,150,122.37 from ¥4,598,026,724.34 at the end of the previous year[19]. - In the first half of 2025, the company achieved operating revenue of ¥1,459,262,003.44, a year-on-year increase of 2.74%, while net profit attributable to the parent company decreased by 63.60% to ¥15,760,805.12[28]. - The company reported a total revenue of 1,000,000,000 CNY for the period, with a year-on-year growth of 15%[76]. - The total revenue for the first half of 2025 was 1.7 billion yuan, showing a year-on-year increase of 9.0%[179]. - The net profit attributable to shareholders reached 794 million yuan, with a profit margin of 46%[179]. Operational Efficiency - The company has implemented measures to enhance operational efficiency, including optimizing organizational structure and achieving precise matching of human resources with business volume[34]. - The average length of hospital stay was reduced to an industry-leading level through standardized clinical pathway management, improving operational efficiency[34]. - The company reported a 5% increase in operational efficiency in its new projects compared to the previous year[65]. - The company has implemented new strategies to improve operational efficiency, aiming for a 3.1% reduction in costs[182]. Strategic Initiatives - The company is committed to addressing risks and implementing corresponding measures as detailed in the management discussion section[3]. - The company plans to expand its operations with a focus on new technology development and market expansion strategies[65]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and expand its service offerings[65]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[177]. - The company has established a strategic partnership with Shanghai University School of Medicine in 2025 to enhance clinical research and high-level talent training in ophthalmology[32]. - The company has focused on developing high-value specialty diseases to balance medical quality and economic benefits amid increasing industry competition[33]. Research and Development - Research and development expenses increased to ¥5,343,459.43 in the first half of 2025, up from ¥4,315,984.56 in the first half of 2024, marking a rise of 23.8%[163]. - The company has allocated 1,464 million RMB for research and development to enhance its service offerings and operational efficiency[186]. - The company introduced advanced technologies such as the new generation robotic femtosecond VISUMAX 800 and minimally invasive femtosecond precision 4.0 system to enhance its technical leadership in key specialties[31]. Market Presence - The company operates 36 hospitals and 4 outpatient departments across more than 20 cities in China, focusing on a direct chain operation model[26]. - The company has opened 36 chain ophthalmology specialty hospitals and 4 ophthalmology clinics, covering all municipalities and over ten provincial capitals, with a focus on regional integration and national chain strategy[35]. - The company plans to expand its market presence by opening 10 new clinics in the next fiscal year[180]. Corporate Governance and Compliance - The financial report was confirmed as true, accurate, and complete by the company's management, including the legal representative and accounting head[3]. - The semi-annual financial report has not been audited[95]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[97]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[93]. - The company has not engaged in any major related party transactions during the reporting period[100]. Social Responsibility and ESG - The company has committed to social responsibility initiatives, including providing assistance to over 30 students with strabismus[90]. - The company’s ESG rating improved to grade A after the disclosure of its third ESG report in April 2025, reflecting its commitment to sustainable development[41]. - The company has actively integrated sustainable development concepts into its daily operations and management, enhancing its ESG governance capabilities[90]. Financial Management - The company reported a significant reduction in investment cash flow, improving by 65.14% to approximately -¥177.96 million, compared to -¥510.53 million in the previous year due to all newly established hospitals being operational[45]. - The company achieved a funding utilization rate of 100% for its liquidity projects, indicating effective capital management[65]. - The company has permanently supplemented working capital with surplus raised funds totaling RMB 30.25 million as of June 30, 2025, from various hospital construction projects[68]. Lease Agreements - The company has signed multiple lease agreements for properties across various cities, with lease terms extending up to 2040[110]. - Significant lease agreements include properties in major cities like Shenzhen and Harbin, with terms ranging from 2024 to 2034[126]. - The company has engaged in long-term leases, indicating a strategy for stable operational bases across various regions[128].